{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:39:42Z","timestamp":1791272382018,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C11591\/A16416"],"award-info":[{"award-number":["C11591\/A16416"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C5759\/A12328"],"award-info":[{"award-number":["C5759\/A12328"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C5759\/A20971"],"award-info":[{"award-number":["C5759\/A20971"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AICR","award":["12-0235"],"award-info":[{"award-number":["12-0235"]}]},{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54CA163125"],"award-info":[{"award-number":["U54CA163125"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["K08CA160692"],"award-info":[{"award-number":["K08CA160692"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancercell.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cell"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ccell.2016.02.003","type":"journal-article","created":{"date-parts":[[2016,3,14]],"date-time":"2016-03-14T12:47:48Z","timestamp":1457959668000},"page":"270-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":241,"title":["Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Michael P.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Brunton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily J.","family":"Rowling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imanol","family":"Arozarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Miskolczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria R.","family":"Girotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell P.","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennie T.","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith T.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wellbrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ccell.2016.02.003_bib1","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1172\/JCI65780","article-title":"Melanoma adapts to RAF\/MEK inhibitors through FOXD3-mediated upregulation of ERBB3","volume":"123","author":"Abel","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ccell.2016.02.003_bib2","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nature12625","article-title":"The causes and consequences of genetic heterogeneity in cancer evolution","volume":"501","author":"Burrell","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.02.003_bib3","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2016.02.003_bib4","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/j.1755-148X.2009.00603.x","article-title":"SKI knockdown inhibits human melanoma tumor growth in\u00a0vivo","volume":"22","author":"Chen","year":"2009","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","article-title":"Anti-HIV drugs for cancer therapeutics: back to the future?","volume":"10","author":"Chow","year":"2009","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ccell.2016.02.003_bib6","doi-asserted-by":"crossref","first-page":"10686","DOI":"10.1158\/0008-5472.CAN-05-2632","article-title":"Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin","volume":"65","author":"da Rocha Dias","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2004.10.014","article-title":"Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF","volume":"6","author":"Du","year":"2004","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2016.02.003_bib8","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","article-title":"BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma","volume":"19","author":"Frederick","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CCO.0b013e328363dfee","article-title":"Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention","volume":"25","author":"Gantt","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ccell.2016.02.003_bib10","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-07-0161","article-title":"Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in\u00a0vitro and in\u00a0vivo","volume":"13","author":"Gills","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2016.02.003_bib12","doi-asserted-by":"crossref","first-page":"8736","DOI":"10.1158\/0008-5472.CAN-10-0902","article-title":"Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells","volume":"70","author":"Gopal","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib13","doi-asserted-by":"crossref","first-page":"7037","DOI":"10.1158\/0008-5472.CAN-14-1392","article-title":"Inhibition of mTORC1\/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1alpha and oxidative phosphorylation in melanoma","volume":"74","author":"Gopal","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1593\/neo.07124","article-title":"The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response","volume":"9","author":"Gupta","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.ccell.2016.02.003_bib15","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2016.02.003_bib16","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1073\/pnas.1205575110","article-title":"BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition","volume":"110","author":"Haq","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.02.003_bib17","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1038\/jid.2015.105","article-title":"MITF modulates therapeutic resistance through EGFR signaling","volume":"135","author":"Ji","year":"2015","journal-title":"J.\u00a0Invest. Dermatol."},{"key":"10.1016\/j.ccell.2016.02.003_bib18","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/0008-5472.CAN-06-3377","article-title":"HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest","volume":"67","author":"Jiang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib19","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/nature12688","article-title":"A melanocyte lineage program confers resistance to MAP kinase pathway inhibition","volume":"504","author":"Johannessen","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.02.003_bib20","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1755-148X.2008.00514.x","article-title":"Pigmentation PAX-ways: the role of Pax3 in melanogenesis, melanocyte stem cell maintenance, and disease","volume":"21","author":"Kubic","year":"2008","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib21","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ccell.2016.02.003_bib22","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ccell.2016.02.003_bib23","doi-asserted-by":"crossref","first-page":"5694","DOI":"10.1038\/ncomms6694","article-title":"Increased MAPK reactivation in early resistance to dabrafenib\/trametinib combination therapy of BRAF-mutant metastatic melanoma","volume":"5","author":"Long","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2016.02.003_bib24","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ccell.2016.02.003_bib25","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1086\/515312","article-title":"A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection","volume":"177","author":"Markowitz","year":"1998","journal-title":"J.\u00a0Infect Dis."},{"key":"10.1016\/j.ccell.2016.02.003_bib26","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1038\/onc.2014.432","article-title":"A stress-induced early innate response causes multidrug tolerance in melanoma","volume":"34","author":"Menon","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ccell.2016.02.003_bib27","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Muller","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ccell.2016.02.003_bib28","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.02.003_bib29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1038\/nature14336","article-title":"Therapy-induced tumour secretomes promote resistance and tumour progression","volume":"520","author":"Obenauf","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.02.003_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00280-012-1961-4","article-title":"Phase I study of nelfinavir in liposarcoma","volume":"70","author":"Pan","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ccell.2016.02.003_bib31","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib32","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-13-0779","article-title":"BRAF in melanoma: current strategies and future directions","volume":"19","author":"Salama","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","article-title":"A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations","volume":"141","author":"Sharma","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.ccell.2016.02.003_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","article-title":"Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy","volume":"4","author":"Shi","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2016.02.003_bib35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.7150\/ijbs.9224","article-title":"Recent advances in drug repositioning for the discovery of new anticancer drugs","volume":"10","author":"Shim","year":"2014","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ccell.2016.02.003_bib36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/jnci\/djs471","article-title":"Effect of SMURF2 targeting on susceptibility to MEK inhibitors in melanoma","volume":"105","author":"Smith","year":"2013","journal-title":"J.\u00a0Natl. Cancer Inst."},{"key":"10.1016\/j.ccell.2016.02.003_bib37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ccell.2016.02.003_bib38","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ccell.2016.02.003_bib39","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/ncb1994","article-title":"Cell fate decisions are specified by the dynamic ERK interactome","volume":"11","author":"von Kriegsheim","year":"2009","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ccell.2016.02.003_bib40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/pcmr.12370","article-title":"Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy","volume":"28","author":"Wellbrock","year":"2015","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.ccell.2016.02.003_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1083\/jcb.200505059","article-title":"Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation","volume":"170","author":"Wellbrock","year":"2005","journal-title":"J.\u00a0Cell Biol."},{"key":"10.1016\/j.ccell.2016.02.003_bib42","doi-asserted-by":"crossref","first-page":"e2734","DOI":"10.1371\/journal.pone.0002734","article-title":"Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF","volume":"3","author":"Wellbrock","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ccell.2016.02.003_bib43","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1101\/gad.14.3.301","article-title":"c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi","volume":"14","author":"Wu","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.ccell.2016.02.003_bib44","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.1073\/pnas.090097797","article-title":"Ski acts as a co-repressor with Smad2 and Smad3 to regulate the response to type beta transforming growth factor","volume":"97","author":"Xu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ccell.2016.02.003_bib45","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.molcel.2008.11.002","article-title":"Inhibition of PAX3 by TGF-beta modulates melanocyte viability","volume":"32","author":"Yang","year":"2008","journal-title":"Mol. Cell"}],"container-title":["Cancer Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561081630037X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S153561081630037X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T23:24:15Z","timestamp":1655249055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S153561081630037X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S153561081630037X"],"URL":"https:\/\/doi.org\/10.1016\/j.ccell.2016.02.003","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726218334.793525701","asserted-by":"object"}]},"ISSN":["1535-6108"],"issn-type":[{"value":"1535-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy","name":"articletitle","label":"Article Title"},{"value":"Cancer Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2016.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ccell.2016.02.014","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}